Scholarlink

Summary <p>Patients with rheumatoid arthritis have higher fracture risks than those without RA, particularly in seropositive cases. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further large-scale studies. Our findings highlight the need for active surveillance and timely intervention in RA patients, particularly those with SPRA and regardless of bDMARD or tsDMARD use.</p> Objectives <p>Evidence of the association between the serological status and the risk of fracture among patients with rheumatoid arthritis (RA) considering exposure to disease-modifying antirheumatic drugs (DMARDs) is scarce. We investigated the risk of fracture among patients with RA according to the serological status considering exposures to biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).</p> Methods <p>We conducted a population-based retrospective cohort study using the Korean National Health Insurance Service database including patients who were diagnosed with RA between 2010 and 2017 (<i>n</i> = 43,677) and controls matched according to age and sex (<i>n</i> = 131,031).</p> Results <p>Patients with RA had a higher risk of any fractures compared to matched controls (adjusted hazard ratio [aHR] 1.68, 95% confidence interval [CI] 1.62‒1.75). Patients with seropositive RA (SPRA) had an increased risk of fracture (aHR 1.19, 95% CI 1.11‒1.28 for any fractures; aHR 1.40, 95% CI 1.26‒1.55 for vertebral fractures; aHR 1.55, 95% CI 1.19‒2.02 for hip fractures) compared to those with seronegative RA. Compared to matched controls, RA patients showed higher fracture risk regardless of bDMARDs (exposed: 2.28-fold; unexposed: 1.64-fold) or tsDMARDs (exposed: 1.91-fold; unexposed: 1.68-fold).</p> Conclusion <p>Patients with RA were at higher risk of fractures compared to those without RA, with even higher risk among those with SPRA. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further studies to explore the impact of bDMARDs and tsDMARDs on fracture risk in patients with RA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of fracture among patients with rheumatoid arthritis according to serological status: a population-based retrospective cohort study

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Seonghye Kim,
  • Kyung-Do Han,
  • Jinhyung Jung,
  • Hyeonjin Cho,
  • Seonyoung Kang,
  • Hyungjin Kim,
  • In Young Cho,
  • Dong Wook Shin

摘要

Summary

Patients with rheumatoid arthritis have higher fracture risks than those without RA, particularly in seropositive cases. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further large-scale studies. Our findings highlight the need for active surveillance and timely intervention in RA patients, particularly those with SPRA and regardless of bDMARD or tsDMARD use.

Objectives

Evidence of the association between the serological status and the risk of fracture among patients with rheumatoid arthritis (RA) considering exposure to disease-modifying antirheumatic drugs (DMARDs) is scarce. We investigated the risk of fracture among patients with RA according to the serological status considering exposures to biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).

Methods

We conducted a population-based retrospective cohort study using the Korean National Health Insurance Service database including patients who were diagnosed with RA between 2010 and 2017 (n = 43,677) and controls matched according to age and sex (n = 131,031).

Results

Patients with RA had a higher risk of any fractures compared to matched controls (adjusted hazard ratio [aHR] 1.68, 95% confidence interval [CI] 1.62‒1.75). Patients with seropositive RA (SPRA) had an increased risk of fracture (aHR 1.19, 95% CI 1.11‒1.28 for any fractures; aHR 1.40, 95% CI 1.26‒1.55 for vertebral fractures; aHR 1.55, 95% CI 1.19‒2.02 for hip fractures) compared to those with seronegative RA. Compared to matched controls, RA patients showed higher fracture risk regardless of bDMARDs (exposed: 2.28-fold; unexposed: 1.64-fold) or tsDMARDs (exposed: 1.91-fold; unexposed: 1.68-fold).

Conclusion

Patients with RA were at higher risk of fractures compared to those without RA, with even higher risk among those with SPRA. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further studies to explore the impact of bDMARDs and tsDMARDs on fracture risk in patients with RA.